ID   P1.HTR
AC   CVCL_4265
SY   P1.HTR1; P1.B5.4.8.12.16.2
DR   CLO; CLO_0008289
DR   CLDB; cl3803
DR   ECACC; 87121104
DR   Wikidata; Q54937216
RX   PubMed=3929396;
RX   PubMed=8609411;
RX   PubMed=9310829;
RX   PubMed=18432777;
CC   Characteristics: Highly transfectable (ECACC=87121104).
CC   Selected for resistance to: ChEBI; CHEBI_472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; Q9QNF7; Human herpesvirus 1 TK.
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21632; Mouse mast cell neoplasm
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_F735 ! P815-X2
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 15
//
RX   PubMed=3929396; DOI=10.1007/BF01534840;
RA   Van Pel A., De Plaen E., Boon T.;
RT   "Selection of highly transfectable variant from mouse mastocytoma
RT   P815.";
RL   Somat. Cell Mol. Genet. 11:467-475(1985).
//
RX   PubMed=8609411; DOI=10.4049/jimmunol.156.8.2909;
RA   Gajewski T.F., Fallarino F., Uyttenhove C., Boon T.;
RT   "Tumor rejection requires a CTLA4 ligand provided by the host or
RT   expressed on the tumor: superiority of B7-1 over B7-2 for active
RT   tumor immunization.";
RL   J. Immunol. 156:2909-2917(1996).
//
RX   PubMed=9310829; DOI=10.1093/intimm/9.9.1259;
RA   Fallarino F., Ashikari A., Boon T., Gajewski T.F.;
RT   "Antigen-specific regression of established tumors induced by active
RT   immunization with irradiated IL-12- but not B7-1-transfected tumor
RT   cells.";
RL   Int. Immunol. 9:1259-1269(1997).
//
RX   PubMed=18432777; DOI=10.1002/0471142735.im2004s43;
RA   Gajewski T.F., Markiewicz M.A., Uyttenhove C.;
RT   "The P815 mastocytoma tumor model.";
RL   Curr. Protoc. Immunol. 43:20.4.1-20.4.18(2001).
//